Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro, 2019, Govegnano et al.

[Jaybee00]

https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-019-1565-6

Results
In vivo, both doses of 10 and 50 mg/kg qd baricitinib crossed the BBB and reversed behavioral abnormalities conferred by HIV infection. Moreover, baricitinib significantly reduced HIV-induced neuroinflammation marked by glial activation: activated microglia (MHCII+/CD45+) and astrogliosis (GFAP). Baricitinib also significantly reduced the percentage of p24+ human macrophages in mouse brains (p < 0.05 versus HAND mice; t test).

https://en.wikipedia.org/wiki/Baricitinib

 

[Jaybee00]

CNS penetration of potential anti-COVID-19 drugs

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195609/

 

[Jaybee00]

@Jonathan Edwards

Any experience with baricitinib? I know you are not a fan of JAK inhibitors for ME/CFS, but might there be some potential for this drug to reduce glial activation?

Thank you.

 

[Jaybee00]

https://finance.yahoo.com/amphtml/news/eli-lillys-arthritis-drug-gets-034748143.html

Eli Lilly's Arthritis Drug Gets Emergency Use Approval For Treatment Of COVID-19

 

[Trish]

A post has been moved to start a new thread:
Neuroinflammation, Neuroautoimmunity, and the Co-Morbidities of Complex Regional Pain Syndrome, 2013, Cooper, Clark